Nephrotoxicity of Amphotericin B

Butler, William T.; Bennett, John E.; Alling, David W.; Wertlake, Paul T.; Utz, John P.; Hill, George J.

doi:10.7326/0003-4819-61-2-175

Cited by 297 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9 Glomerular abnormalities have been observed after amphotericin therapy but are not as frequent or marked as tubular changes. 10,11 Glomuerulosclerosis in 3 of our patients may have been the result of an abnormality intrinsic to HIES, which may relate to other connective tissue abnormalities of the syndrome. Kidney disease is not typically associated with HIES, but perhaps, as patients with HIES live longer with improved antimicrobial therapy, more renal dysfunction and abnormalities will become apparent.…”

Section: Discussionmentioning

confidence: 72%

Causes of death in hyper-IgE syndrome

Freeman

Kleiner²,

Nadiminti

et al. 2007

Journal of Allergy and Clinical Immunology

155

121

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 72%

Causes of death in hyper-IgE syndrome

Freeman

Kleiner²,

Nadiminti

et al. 2007

Journal of Allergy and Clinical Immunology

155

121

View full text Add to dashboard Cite

“…Furthermore, there appeared to be no significant increase in serum creatinine levels with ABCD even in patients with pre-existing renal failure [70]. This low rate of nephrotoxicity of ABCD is particularly significant when compared to the high rate of azotemia (26-83% of patients at varying doses) caused by amphotericin B deoxycholate [71,72]. It has been shown that ABCD can cause renal tubular damage but only at doses that are 5 to 8 times higher than that of amphotericin B deoxycholate [73].…”

Section: Animal Datamentioning

confidence: 79%

Lipid-based Antifungal Agents Current Status

Arıkan¹,

Rex

2001

CPD

View full text Add to dashboard Cite

Immunocompromised patients are well known to be predisposed to developing invasive fungal infections. These infections are usually difficult to diagnose and more importantly, the resulting mortality rate is high. The limited number of antifungal agents available and their high rate of toxicity are the major factors complicating the issue. However, the development of lipid-based formulations of existing antifungal agents has opened a new era in antifungal therapy. The best examples are the lipid-based amphotericin B preparations, amphotericin B lipid complex (ABLC; Abelcet), amphotericin B colloidal dispersion (ABCD; Amphotec or Amphocil), and liposomal amphotericin B (AmBisome). These formulations have shown that antifungal activity is maintained while toxicity is reduced. This progress is followed by the incorporation of nystatin into liposomes. Liposomal nystatin formulation is under development and studies of it have provided encouraging data. Finally, lipid-based formulations of hamycin, miconazole, and ketoconazole have been developed but remain experimental. Advances in technology of liposomes and other lipid formulations have provided promising new tools for management of fungal infections.

show abstract

“…ADV infection caused varying degrees of renal failure in different patients. It is likely that drug nephrotoxicity (20,22) as well as hypotension contributed to kidney compromise in some others (Table 4). Among the 18 allograft recipients with ARF, the most frequent clinical findings were persistent gross hematuria beginning at a median of day 50 in 14 (78%) patients and adenoviruria first documented in 14 (78%) patients at a median of day 52 (Table 4).…”

Section: Causes and Clinical Interpretation Of Arfmentioning

confidence: 98%